Teva: Feeling the Weight of Generic Competition

Profits from Teva's (NYSE: TEVA  ) flagship drug, Copaxone, may be in jeopardy. The company just lost a major court case, invalidating a key patent, that will allow generic versions of the multiple sclerosis drug to market by May 2014, a full 16 months early. In this video, Motley Fool health-care analyst David Williamson discusses just how much this compressed timeline is going to hurt Teva and what he'll be looking for with the company going forward.

It's no secret that biotech stocks have been soaring recently, but the best investment strategy is to pick great companies and stick with them for the long term. The Motley Fool's free report "3 Stocks That Will Help You Retire Rich" not only shares stocks that could help you build long-term wealth, but also winning strategies that every investor should know. Click here to grab your free copy today.


Read/Post Comments (0) | Recommend This Article (0)

Comments from our Foolish Readers

Help us keep this a respectfully Foolish area! This is a place for our readers to discuss, debate, and learn more about the Foolish investing topic you read about above. Help us keep it clean and safe. If you believe a comment is abusive or otherwise violates our Fool's Rules, please report it via the Report this Comment Report this Comment icon found on every comment.

Be the first one to comment on this article.

Sponsored Links

Leaked: Apple's Next Smart Device
(Warning, it may shock you)
The secret is out... experts are predicting 458 million of these types of devices will be sold per year. 1 hyper-growth company stands to rake in maximum profit - and it's NOT Apple. Show me Apple's new smart gizmo!

DocumentId: 2570915, ~/Articles/ArticleHandler.aspx, 11/28/2014 1:40:26 PM

Report This Comment

Use this area to report a comment that you believe is in violation of the community guidelines. Our team will review the entry and take any appropriate action.

Sending report...


Advertisement